X0306 4 2021-06-15 1 0001817713 Janux Therapeutics, Inc. JANX 0001863287 Bregua Corp WICKHAMS CAY P.O. BOX 146 ROAD TOWN, TORTOLA D8 VG1110 VIRGIN ISLANDS, BRITISH 0 0 1 0 Common Stock 2021-06-15 4 C 0 1138665 A 1138665 D Common Stock 2021-06-15 4 C 0 1630428 A 2769093 D Common Stock 2021-06-15 4 C 0 674211 A 3443304 D Common Stock 2021-06-15 4 C 0 247123 A 3690427 D Common Stock 2021-06-15 4 P 0 58823 17.00 A 3749250 D Series Seed Convertible Preferred Stock 2021-06-15 4 C 0 888888 D Common Stock 1138665 0 D Series Seed 2 Convertible Preferred Stock 2021-06-15 4 C 0 1272778 D Common Stock 1630428 0 D Series A Convertible Preferred Stock 2021-06-15 4 C 0 526316 D Common Stock 674211 0 D Series B Convertible Preferred Stock 2021-06-15 4 C 0 192914 D Common Stock 247123 0 D Each share of Series Seed Convertible Preferred Stock, Series Seed 2 Convertible Preferred Stock, Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into 1.281 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. These securities are held directly by Bregua Corporation (Bregua). Klaus Dorner is the Director of Bregua and may be deemed to have voting and investment power with respect to the shares held by Bregua and as a result may be deemed to have beneficial ownership of such shares. Mr. Dorner disclaims beneficial ownership of all shares held by Bregua, except to the extent of his actual pecuniary interest therein, if any. The shares were purchased in the Issuer's initial public offering. /s/ Klaus Dorner, Director of Bregua Corporation 2021-06-16